Long-Term Dominance of Carbapenem-Non-Susceptible Pseudomonas aeruginosa ST111 in Hematologic Malignancy Patients and Hematopoietic Cell Transplant Recipients

Simple item page
dc.citation.articleNumber904602en_US
dc.citation.journalTitleFrontiers in Cellular and Infection Microbiologyen_US
dc.citation.volumeNumber12en_US
dc.contributor.authorZhang, Liyangen_US
dc.contributor.authorTan, Filemon C.en_US
dc.contributor.authorStrasfeld, Lynneen_US
dc.contributor.authorHakki, Morganen_US
dc.contributor.authorKirienko, Natalia V.en_US
dc.date.accessioned2022-08-04T14:53:21Zen_US
dc.date.available2022-08-04T14:53:21Zen_US
dc.date.issued2022en_US
dc.description.abstractAn epidemiological study uncovered that fluoroquinolone (FQ) neutropenic prophylaxis in hematopoietic cell transplant and hematologic malignancy (HCT/HM) patients was associated with breakthrough Pseudomonas aeruginosa bloodstream infections (BSIs) with isolates non-susceptible to both FQs and meropenem. The molecular epidemiology of the FQ/meropenem-non-susceptible P. aeruginosa isolates causing FQ-breakthrough BSIs in the HCT/HM patients remains unclear. Through whole genome sequencing on 57 P. aeruginosa isolates from 54 patients diagnosed with HM or receiving an HCT, we found that ST111 strains predominated, accounting for 22 (38.6%) of the isolates. 17 of 33 (51.5%) FQ-breakthrough BSIs were caused by ST111 strains, of which 15 (88.2%) were meropenem non-susceptible. ST111 strains, but not other oprD-deficient, meropenem-non-susceptible clinical strains, were found to have a colonization advantage over P. aeruginosa strain PA14 in C. elegans and to outcompete PA14 in in vitro co-culture assays. Together, we found that breakthrough P. aeruginosa BSIs during FQ prophylaxis in HCT/HM patients are dominated by clonally-related FQ/meropenem non-susceptible strains, predominantly ST111 type, and that the dominance of ST111 strains may be explained by a relative fitness advantage over other clinical strains. Additional work is necessary to better understand the factors driving the dominance and persistence of these ST111 strains.en_US
dc.identifier.citationZhang, Liyang, Tan, Filemon C., Strasfeld, Lynne, et al.. "Long-Term Dominance of Carbapenem-Non-Susceptible Pseudomonas aeruginosa ST111 in Hematologic Malignancy Patients and Hematopoietic Cell Transplant Recipients." <i>Frontiers in Cellular and Infection Microbiology,</i> 12, (2022) Frontiers Media S.A.: https://doi.org/10.3389/fcimb.2022.904602.en_US
dc.identifier.digitalfcimb-12-904602en_US
dc.identifier.doihttps://doi.org/10.3389/fcimb.2022.904602en_US
dc.identifier.urihttps://hdl.handle.net/1911/112969en_US
dc.language.isoengen_US
dc.publisherFrontiers Media S.A.en_US
dc.rightsThis is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.en_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en_US
dc.titleLong-Term Dominance of Carbapenem-Non-Susceptible Pseudomonas aeruginosa ST111 in Hematologic Malignancy Patients and Hematopoietic Cell Transplant Recipientsen_US
dc.typeJournal articleen_US
dc.type.dcmiTexten_US
dc.type.publicationpublisher versionen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
fcimb-12-904602.pdf
Size:
2.02 MB
Format:
Adobe Portable Document Format
Download
Collections
Faculty Publications
BioSciences Publications